Immunogenicity and safety of co-immunization with 23-valent pneumococcal polysaccharide vaccine and influenza virus split vaccine for children aged 3-7 years
10.3760/cma.j.issn.0254-5101.2019.10.006
- VernacularTitle:3～7岁儿童同时接种23价肺炎球菌多糖疫苗和流感病毒裂解疫苗的免疫原性及安全性研究
- Author:
Zhiguo WANG
1
;
Xiang SUN
;
Min ZHANG
;
Fenyang TANG
;
Fubao MA
;
Yan XU
;
Ran HU
;
Yanli MA
;
Yanhui XIAO
;
Haiping CHEN
;
Linyun LUO
Author Information
1. 江苏省疾病预防控制中心免疫规划所
- Keywords:
Pneumococcal polysaccharide vaccine (PPV23);
Trivalent influenza vaccine (TIV);
Preschoolers;
Safety;
Immunogenicity
- From:Chinese Journal of Microbiology and Immunology
2019;39(10):758-762
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the immunogenicity and safety of concomitant administration of 23-valent pneumococcal polysaccharide vaccine ( PPV23) and trivalent influenza vaccine ( TIV) in pre-schoolers. Methods A total of 1035 children aged 3-7 years were enrolled in this study and randomly di-vided into three groups, inoculated PPV23, TIV and both, respectively. A one-year follow-up study was conducted for immunogenicity and safety analysis. Results A total of 1035 serological specimens were col-lected, including 327 in PPV23 group, 348 in TIV group and 360 in concomitant vaccination group. No sig-nificant differences in geometric mean concentrations (GMC) of seven pneumococcal serotypes were observed between the PPV23 group and the concomitant vaccination group. Compared with the TIV group, the con-comitant vaccination group showed higher serological conversion rate of H3 type (88. 75％ vs 84. 20％ , P=0. 01), but lower serological conversion rate of B type (92. 84％ vs 98. 56％ , P<0. 001). There was no significant difference in the primary adverse reactions between the three groups (P = 0. 197). The rate of secondary adverse reactions occurred in the concomitant vaccination group was 3. 61％ , which was higher than that of the other two groups (both P<0. 001). All adverse reactions were mild or moderate, and cured after treatment. Conclusions Concomitant immunization with PPV23 and TIV is safe and have good immu-nogenicity, thus a viable immune strategy for susceptible children.
